ViatrisHAM:VIA +1.71%58 Net Margin % is 5.02% as of Mar. 2026, which is 1908% above its 10-year median of 0.25. GuruFocus rates HAM:VIA with a GF Score™ of 58/100 and a GF Value™ of €9.77 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 956 Drug Manufacturers companies, Viatris ranks worse than 68.93% on this metric.
Net margin is calculated as Net Income divided by its Revenue. Viatris's Net Income for the
three
months ended in Mar. 2026 was €153 Mil. Viatris's Revenue for the
three
months ended in Mar. 2026 was €3,042 Mil. Therefore, Viatris's net margin for the quarter that ended in Mar. 2026 was 5.02%.
The historical rank and industry rank for Viatris's Net Margin % or its related term are showing as below:
HAM:VIA'
s Net Margin % Range Over the Past 10 Years
Min: -24.58 Med: 0.25 Max: 12.78
Current: -2.04
HAM:VIA's Net Margin % is ranked worse than 68.93% of 956
companies
in the Drug Manufacturers industry
Industry Median: 5.56
vs HAM:VIA: -2.04
Viatris (HAM:VIA) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Viatris Net Margin % Related Terms
Viatris Net Margin % Historical Data
* Premium members only.
The historical data trend for Viatris's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HAM:VIA vs NBIX, UTHR, ELAN: Net Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Viatris's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Viatris Net Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Viatris's Net Margin % distribution charts can be found below:
* The bar in red indicates where Viatris's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Viatris (HAM:VIA) has a Net Margin % of 5.02% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Viatris and its competitors. This is 1908% above median its historical median of 0.25. According to the industry distribution chart, Viatris ranks #659 out of 956 companies in the Drug Manufacturers industry, placing it in the top 68.9%.
Is Viatris' Net Margin % too high?
Viatris' current Net Margin % of 5.02% is 1908% above median its 10-year median of 0.25. The Drug Manufacturers industry median Net Margin % is 5.56. Viatris' value of 5.02% is 9.7% below this industry median. Based on the distribution chart, Viatris ranks #659 out of 956 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Viatris has a GF Score™ of 58/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Viatris' Net Margin % compare to NBIX and UTHR?
According to the Drug Manufacturers industry distribution chart, Viatris ranks #659 out of 956 companies for Net Margin %. This places Viatris in the lower half of its industry. The industry median Net Margin % is 5.56. Viatris' value of 5.02% is 9.7% below this benchmark. While the company's 10-year median is 0.25 vs. the industry median of 5.56, Viatris has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.56, based on 956 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Viatris's current Net Margin % of 5.02% is 9.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Viatris and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Viatris's current Net Margin % is 5.02%, which is 1908% above median its own 10-year median of 0.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Viatris stock overvalued right now?
Based on GuruFocus' analysis, Viatris (HAM:VIA) is currently considered Significantly Overvalued. The stock's GF Value™ is €9.77, compared to a current price of €14.26 — trading 45.9% above its estimated fair value. The current Net Margin % is 5.02%, which is 1908% above median its 10-year median of 0.25 and 9.7% below the Drug Manufacturers industry median of 5.56. Viatris' overall GF Score™ is 58/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Viatris (HAM:VIA), the current Net Margin % is 5.02% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Viatris (HAM:VIA) Overvalued in 2026?
Based on GuruFocus' analysis, Viatris stock appears to be overvalued.
The current stock price of €14.26 is trading 45.9% above its estimated GF Value™ of €9.77.
GuruFocus considers Viatris to be Significantly Overvalued.
Key valuation signals for HAM:VIA:
Net Margin %: 5.02% (1908% above median its 10-year median of 0.25)
GF Value™: €9.77 vs. price of €14.26 (45.9% above fair value)
Industry Position: 9.7% below the Drug Manufacturers median (#659 of 956)
No single metric tells the full story. See the HAM:VIA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.
58GF Score
Get the complete analysis for HAM:VIA
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAM:VIA has been successfully added to your 
